Press Resease

Hemoglobinopathies Market: by Indication (sickle cell disease, alpha thalassemia, beta thalassemia and others), Therapy (blood transfusion, iron chelation therapy, bone marrow transplant, and others), Diagnosis (blood testing, genetic testing, pre-implantation genetic diagnosis (PGD) and others), End user (Hospitals, Diagnostic laboratories, Clinics, Other End-user) – Global Industry Perspective Comprehensive Analysis and Forecast, 2019-2025

Published Date: 24-Oct-2019 Category: Healthcare Report Format : PDF Pages: 130 Report Code: ZMR-4918 Status : Published

According to the report, global demand for Hemoglobinopathies market was valued at approximately USD 5,790.0 million in 2018, and is expected to generate revenue of around USD 11,409.84 million by end of 2025, growing at a CAGR of around 10.25% between 2019 and 2025.

Description

The report covers forecast and analysis for the Hemoglobinopathies market on a global and regional level. The study provides historic data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the Hemoglobinopathies market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Hemoglobinopathies market on a global level. In order to give the users of this report a comprehensive view on the Hemoglobinopathies market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein indication, therapy, diagnosis, end-user, and regional segments are benchmarked based on their market size, growth rate and general attractiveness.

Hemoglobinopathies are formed as a result of gene defects and anemia. The development of abnormal hemoglobin is found in three circumstances such as structural defects in the molecule of hemoglobin, reduced production of one of the two subunits of the molecule of hemoglobin, and irregular associations of otherwise healthy subunits. There may be serious or moderate illnesses. The most common tools / tests for hemoglobinopathy diagnosis and thalassemia disorders are genetic diagnosis preimplantation, genetic and blood testing, electrophoresis of alkaline and acid gel, electrophoresis of hemoglobin, genetic prenatal testing and chromatography of ion exchange HbA2.

Global Hemoglobinopathies Market

The study provides a decisive view on the Hemoglobinopathies market by segmenting the market based on treatment product, application, technique, end user and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. Based on Indication, the market is segmented into sickle cell disease, alpha thalassemia, beta thalassemia and others. In 2018, SCD was the largest sales group. Due to increasing efforts to improve patient understanding of the condition and subsequent progress in diagnosis and treatment, the segment is also projected to grow over the forecast period at a healthy CAGR.

Based on therapy, the market is segmented into Blood Transfusion, Iron Chelation Therapy, Bone Marrow Transplant and Others. In 2018, blood transfusion therapy held the largest market share. Increasing the number of blood donations in government initiatives is a high impact making factor for the hemoglobinopathy market.

Based on diagnosis, the market is segmented into          blood testing, genetic testing, pre-implantation genetic diagnosis (PGD) and others. Blood testing led revenue-related treatment segment in 2018. A key contributor to its major market share is the fact that blood testing is widely used as the first-line screening process. Due to its efficacy in accurate diagnosis and monitoring, genetic testing for SCD diagnosis is projected to be the fastest growing segment over the forecast period. Based on end-user, the market is segmented into hospitals, diagnostic laboratories, clinics and other end-user. In 2018, the market dominated by hospitals.

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa with its further bifurcation into major countries such as US, Canada, Germany, UK, France, China, Japan, India, GCC countries, Brazil. Due to rising R&D investments by key players, better reimbursement scenario, and the availability of high-quality healthcare services, North America led the overall revenue market in 2018.

It is expected that increased R&D efforts aimed at developing new treatments would lead to market growth. The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), supports SCD research projects to develop new ways of detecting and treating the disease, as well as enhancing patient outcomes. New procedures that include modifying or deleting the defective SCD gene and transplanting the repaired gene back to the patients are being established using developments in gene-editing technology. Increasing funding for SCD prevention and treatment by enacting legislation such as the Sickle Cell Disease Study, Monitoring, Prevention and Treatment Act, 2018 is also likely to help in enhanced management of the situation.

Key players within global Hemoglobinopathies market include Alnylam Pharmaceuticals, bluebird bio Inc., Celgene Corporation, Emmaus Life Sciences Inc., Gamida Cell, Global Blood Therapeutics, Prolong Pharmaceuticals, Sangamo, Therapeutics Inc., Sanofi amongst others.

The report segments global Hemoglobinopathies market as follows:

Global Hemoglobinopathies Market: Indication Segment Analysis

  • Sickle cell disease
  • Alpha Thalassemia
  • Beta Thalassemia
  • Others

Global Hemoglobinopathies Market: Therapy Segment Analysis

  • Blood Transfusion
  • Iron Chelation Therapy
  • Bone Marrow Transplant
  • Others

Global Hemoglobinopathies Market: Diagnosis Segment Analysis

  • Blood testing
  • Genetic testing
  • Pre-implantation Genetic Diagnosis (PGD)
  • Other

Global Hemoglobinopathies Market: End-user Segment Analysis

  • Hospitals
  • Diagnostic laboratories
  • Clinics
  • Other End-user

Global Hemoglobinopathies Market: Regional Segment Analysis

  • North America
    • U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Hemoglobinopathies Market, 2016-2025 (USD Million)
    • 2.2. Hemoglobinopathies Market: Snapshot
  • Chapter 3. Hemoglobinopathies Market - Industry Analysis
    • 3.1. Hemoglobinopathies Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Driver 1
      • 3.2.2. Driver 2
    • 3.3. Restraints
      • 3.3.1. Restraint 1
      • 3.3.2. Restraint 2
    • 3.4. Opportunity
      • 3.4.1. Government funding and support
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis By Indication
      • 3.6.2. Market attractiveness analysis By Therapy
      • 3.6.3. Market attractiveness analysis By Diagnosis
      • 3.6.4. Market attractiveness analysis By End-user
      • 3.6.5. Market attractiveness analysis by Region
  • Chapter 4. Hemoglobinopathies Market- Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Hemoglobinopathies Market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Indication launches
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Hemoglobinopathies Market -Indication Analysis
    • 5.1. Global Hemoglobinopathies Market overview: By Indication type
      • 5.1.1. Global Hemoglobinopathies Market share, By Indication,2018 and 2025
    • 5.2. Sickle cell disease
      • 5.2.1. Global Hemoglobinopathies Market by Sickle cell disease, 2016-2025 (USD Million)
    • 5.3. Alpha Thalassemia
      • 5.3.1. Global Hemoglobinopathies Market by Alpha Thalassemia, 2016-2025 (USD Million)
    • 5.4. Beta Thalassemia
      • 5.4.1. Global Hemoglobinopathies Market by Beta Thalassemia, 2016-2025 (USD Million)
    • 5.5. Others
      • 5.5.1. Global Hemoglobinopathies Market by others, 2016-2025 (USD Million)
  • Chapter 6. Global Hemoglobinopathies Market -Therapy Analysis
    • 6.1. Global Hemoglobinopathies Market overview: By Therapy
      • 6.1.1. Global Hemoglobinopathies Market share, By Therapy, 2018 and 2025
    • 6.2. Blood Transfusion
      • 6.2.1. Global Hemoglobinopathies Market By Blood Transfusion, 2016-2025 (USD Million)
    • 6.3. Iron Chelation Therapy
      • 6.3.1. Global Hemoglobinopathies Market By Iron Chelation Therapy, 2016-2025 (USD Million)
    • 6.4. Bone Marrow Transplant
      • 6.4.1. Global Hemoglobinopathies Market By Bone Marrow Transplant, 2016-2025 (USD Million)
    • 6.5. Others
      • 6.5.1. Global Hemoglobinopathies Market by Other Therapys, 2016-2025 (USD Million)
  • Chapter 7. Global Hemoglobinopathies Market -Diagnosis Analysis
    • 7.1. Global Hemoglobinopathies Market overview: By Diagnosis
      • 7.1.1. Global Hemoglobinopathies Market share, By Diagnosis, 2018 and 2025
    • 7.2. Blood testing
      • 7.2.1. Global Hemoglobinopathies Market by Blood testing, 2016-2025 (USD Million)
    • 7.3. Genetic testing
      • 7.3.1. Global Hemoglobinopathies Market by Genetic testing, 2016-2025 (USD Million)
    • 7.4. Pre-implantation Genetic Diagnosis (PGD)
      • 7.4.1. Global Hemoglobinopathies Market by Pre-implantation Genetic Diagnosis (PGD), 2016-2025 (USD Million)
    • 7.5. Others
      • 7.5.1. Global Hemoglobinopathies Market by Diagnosis others, 2016-2025 (USD Million)
  • Chapter 8. Global Hemoglobinopathies Market - End-user Analysis
    • 8.1. Global Hemoglobinopathies Market overview: By End-user
      • 8.1.1. Global Hemoglobinopathies Market share, By End-user, 2018 and 2025
    • 8.2. Hospitals
      • 8.2.1. Global Hemoglobinopathies Market by Hospitals, 2016-2025 (USD Million)
    • 8.3. Diagnostic laboratories
      • 8.3.1. Global Hemoglobinopathies Market by Diagnostic laboratories, 2016-2025 (USD Million)
    • 8.4. Clinics
      • 8.4.1. Global Hemoglobinopathies Market by Clinics, 2016-2025 (USD Million)
    • 8.5. Others
      • 8.5.1. Global Hemoglobinopathies Market by End-user Others, 2016-2025 (USD Million)
  • Chapter 9. Global Hemoglobinopathies Market - Regional Analysis
    • 9.1. Global Hemoglobinopathies Market overview: by Region
      • 9.1.1. Global Hemoglobinopathies Market share, by Region, 2018 and 2025
    • 9.2. North America
      • 9.2.1. North America Hemoglobinopathies Market, 2016-2025 (USD Million)
      • 9.2.2. North America Hemoglobinopathies Market revenue, By Indication,2016-2025 (USD Million)
      • 9.2.3. North America Hemoglobinopathies Market revenue, By Therapy, 2016-2025 (USD Million)
      • 9.2.4. North America Hemoglobinopathies Market revenue, By Diagnosis, 2016-2025 (USD Million)
      • 9.2.5. North America Hemoglobinopathies Market revenue, By End-user, 2016-2025 (USD Million)
      • 9.2.6. The U.S.
        • 9.2.6.1. The U.S. Hemoglobinopathies Market revenue, By Indication,2016-2025 (USD Million)
        • 9.2.6.2. The U.S. Hemoglobinopathies Market revenue, By Therapy, 2016-2025 (USD Million)
        • 9.2.6.3. The U.S. Hemoglobinopathies Market revenue, By Diagnosis, 2016-2025 (USD Million)
        • 9.2.6.4. The U.S. Hemoglobinopathies Market revenue, By End-user, 2016-2025 (USD Million)
      • 9.2.7. Rest of North America
        • 9.2.7.1. Rest of North America Hemoglobinopathies Market revenue, By Indication,2016-2025 (USD Million)
        • 9.2.7.2. Rest of North America Hemoglobinopathies Market revenue, By Therapy, 2016-2025 (USD Million)
        • 9.2.7.3. Rest of North America Hemoglobinopathies Market revenue, By Diagnosis, 2016-2025 (USD Million)
        • 9.2.7.4. Rest of North America Hemoglobinopathies Market revenue, By End-user, 2016-2025 (USD Million)
    • 9.3. Europe
      • 9.3.1. Europe Hemoglobinopathies Market, 2016-2025 (USD Million)
      • 9.3.2. Europe Hemoglobinopathies Market revenue, By Indication,2016-2025 (USD Million)
      • 9.3.3. Europe Hemoglobinopathies Market revenue, By Therapy, 2016-2025 (USD Million)
      • 9.3.4. Europe Hemoglobinopathies Market revenue, By Diagnosis, 2016-2025 (USD Million)
      • 9.3.5. Europe Hemoglobinopathies Market revenue, By End-user, 2016-2025 (USD Million)
      • 9.3.6. UK
        • 9.3.6.1. U.K. Hemoglobinopathies Market revenue, By Indication,2016-2025 (USD Million)
        • 9.3.6.2. U.K. Hemoglobinopathies Market revenue, By Therapy, 2016-2025 (USD Million)
        • 9.3.6.3. U.K. Hemoglobinopathies Market revenue, By Diagnosis, 2016-2025 (USD Million)
        • 9.3.6.4. U.K. Hemoglobinopathies Market revenue, By End-user, 2016-2025 (USD Million)
      • 9.3.7. France
        • 9.3.7.1. France Hemoglobinopathies Market revenue, By Indication,2016-2025 (USD Million)
        • 9.3.7.2. France Hemoglobinopathies Market revenue, By Therapy, 2016-2025 (USD Million)
        • 9.3.7.3. France Hemoglobinopathies Market revenue, By Diagnosis, 2016-2025 (USD Million)
        • 9.3.7.4. France Hemoglobinopathies Market revenue, By End-user, 2016-2025 (USD Million)
      • 9.3.8. Germany
        • 9.3.8.1. Germany Hemoglobinopathies Market revenue, By Indication,2016-2025 (USD Million)
        • 9.3.8.2. Germany Hemoglobinopathies Market revenue, By Therapy, 2016-2025 (USD Million)
        • 9.3.8.3. Germany Hemoglobinopathies Market revenue, By Diagnosis, 2016-2025 (USD Million)
        • 9.3.8.4. Germany Hemoglobinopathies Market revenue, By End-user, 2016-2025 (USD Million)
      • 9.3.9. Rest of Europe
        • 9.3.9.1. Rest of Europe Hemoglobinopathies Market revenue, By Indication,2016-2025 (USD Million)
        • 9.3.9.2. Rest of Europe Hemoglobinopathies Market revenue, By Therapy, 2016-2025 (USD Million)
        • 9.3.9.3. Rest of Europe Hemoglobinopathies Market revenue, By Diagnosis, 2016-2025 (USD Million)
        • 9.3.9.4. Rest of Europe Hemoglobinopathies Market revenue, By End-user, 2016-2025 (USD Million)
    • 9.4. Asia Pacific
      • 9.4.1. Asia Pacific Hemoglobinopathies Market, 2016-2025 (USD Million)
      • 9.4.2. Asia Pacific Hemoglobinopathies Market revenue, By Indication,2016-2025 (USD Million)
      • 9.4.3. Asia Pacific Hemoglobinopathies Market revenue, By Therapy, 2016-2025 (USD Million)
      • 9.4.4. Asia Pacific Hemoglobinopathies Market revenue, By Diagnosis, 2016-2025 (USD Million)
      • 9.4.5. Asia Pacific Hemoglobinopathies Market revenue, By End-user, 2016-2025 (USD Million)
      • 9.4.6. China
        • 9.4.6.1. China Hemoglobinopathies Market revenue, By Indication,2016-2025 (USD Million)
        • 9.4.6.2. China Hemoglobinopathies Market revenue, By Therapy, 2016-2025 (USD Million)
        • 9.4.6.3. China Hemoglobinopathies Market revenue, By Diagnosis, 2016-2025 (USD Million)
        • 9.4.6.4. China Hemoglobinopathies Market revenue, By End-user, 2016-2025 (USD Million
      • 9.4.7. Japan
        • 9.4.7.1. Japan Hemoglobinopathies Market revenue, By Indication,2016-2025 (USD Million)
        • 9.4.7.2. Japan Hemoglobinopathies Market revenue, By Therapy, 2016-2025 (USD Million)
        • 9.4.7.3. Japan Hemoglobinopathies Market revenue, By Diagnosis, 2016-2025 (USD Million)
        • 9.4.7.4. Japan Hemoglobinopathies Market revenue, By End-user, 2016-2025 (USD Million)
      • 9.4.8. India
        • 9.4.8.1. India Hemoglobinopathies Market revenue, By Indication,2016-2025 (USD Million)
        • 9.4.8.2. India Hemoglobinopathies Market revenue, By Therapy, 2016-2025 (USD Million)
        • 9.4.8.3. India Hemoglobinopathies Market revenue, By Diagnosis, 2016-2025 (USD Million)
        • 9.4.8.4. India Hemoglobinopathies Market revenue, By End-user, 2016-2025 (USD Million)
      • 9.4.9. Rest of Asia Pacific
        • 9.4.9.1. Rest of Asia Pacific Hemoglobinopathies Market revenue, By Indication,2016-2025 (USD Million)
        • 9.4.9.2. Rest of Asia Pacific Hemoglobinopathies Market revenue, By Therapy, 2016-2025 (USD Million)
        • 9.4.9.3. Rest of Asia Pacific Hemoglobinopathies Market revenue, By Diagnosis, 2016-2025 (USD Million)
        • 9.4.9.4. Rest of Asia Pacific Hemoglobinopathies Market revenue, By End-user, 2016-2025 (USD Million)
    • 9.5. Latin America
      • 9.5.1. Latin America Hemoglobinopathies Market, 2016-2025 (USD Million)
      • 9.5.2. Latin America Hemoglobinopathies Market revenue, By Indication,2016-2025 (USD Million)
      • 9.5.3. Latin America Hemoglobinopathies Market revenue, By Therapy, 2016-2025 (USD Million)
      • 9.5.4. Latin America Hemoglobinopathies Market revenue, By Diagnosis, 2016-2025 (USD Million)
      • 9.5.5. Latin America Hemoglobinopathies Market revenue, By End-user, 2016-2025 (USD Million)
      • 9.5.6. Brazil
        • 9.5.6.1. Brazil Hemoglobinopathies Market revenue, By Indication,2016-2025 (USD Million)
        • 9.5.6.2. Brazil Hemoglobinopathies Market revenue, By Therapy, 2016-2025 (USD Million)
        • 9.5.6.3. Brazil Hemoglobinopathies Market revenue, By Diagnosis, 2016-2025 (USD Million)
        • 9.5.6.4. Brazil Hemoglobinopathies Market revenue, By End-user, 2016-2025 (USD Million)
      • 9.5.7. Rest of LatinAmerica
        • 9.5.7.1. Rest of LatinAmerica Hemoglobinopathies Market revenue, By Indication,2016-2025 (USD Million)
        • 9.5.7.2. Rest of LatinAmerica Hemoglobinopathies Market revenue, By Therapy, 2016-2025 (USD Million)
        • 9.5.7.3. Rest of Latin America Hemoglobinopathies Market revenue, By Diagnosis, 2016-2025 (USD Million)
        • 9.5.7.4. Rest of Latin America Hemoglobinopathies Market revenue, By End-user, 2016-2025 (USD Million)
    • 9.6. The Middle East and Africa
      • 9.6.1. The Middle East and Africa Hemoglobinopathies Market, 2016-2025 (USD Million)
      • 9.6.2. The Middle East and Africa Hemoglobinopathies Market revenue, By Indication,2016-2025 (USD Million)
      • 9.6.3. The Middle East and Africa Hemoglobinopathies Market revenue, By Therapy, 2016-2025 (USD Million)
      • 9.6.4. The Middle East and Africa Hemoglobinopathies Market revenue, By Diagnosis, 2016-2025 (USD Million)
      • 9.6.5. The Middle East and Africa Hemoglobinopathies Market revenue, By End-user, 2016-2025 (USD Million)
  • Chapter 10. Company Profiles
    • 10.1. Alnylam Pharmaceuticals
      • 10.1.1. Overview
      • 10.1.2. Financials
      • 10.1.3. Indication Portfolio
      • 10.1.4. Business Strategy
      • 10.1.5. Recent Developments
    • 10.2. bluebird bio Inc.
      • 10.2.1. Overview
      • 10.2.2. Financials
      • 10.2.3. Indication Portfolio
      • 10.2.4. Business Strategy
      • 10.2.5. Recent Developments
    • 10.3. Celgene Corporation
      • 10.3.1. Overview
      • 10.3.2. Financials
      • 10.3.3. Indication Portfolio
      • 10.3.4. Business Strategy
      • 10.3.5. Recent Developments
    • 10.4. Emmaus Life Sciences Inc.
      • 10.4.1. Overview
      • 10.4.2. Financials
      • 10.4.3. Indication Portfolio
      • 10.4.4. Business Strategy
      • 10.4.5. Recent Developments
    • 10.5. Gamida Cell
      • 10.5.1. Overview
      • 10.5.2. Financials
      • 10.5.3. Indication Portfolio
      • 10.5.4. Business Strategy
      • 10.5.5. Recent Development
    • 10.6. Global Blood Therapeutics
      • 10.6.1. Overview
      • 10.6.2. Financials
      • 10.6.3. Indication Portfolio
      • 10.6.4. Business Strategy
      • 10.6.5. Recent Development
    • 10.7. Prolong Pharmaceuticals
      • 10.7.1. Overview
      • 10.7.2. Financials
      • 10.7.3. Indication Portfolio
      • 10.7.4. Business Strategy
      • 10.7.5. Recent Development
    • 10.8. Sangamo
      • 10.8.1. Overview
      • 10.8.2. Financials
      • 10.8.3. Indication Portfolio
      • 10.8.4. Business Strategy
      • 10.8.5. Recent Development
    • 10.9. Therapeutics Inc.
      • 10.9.1. Overview
      • 10.9.2. Financials
      • 10.9.3. Indication Portfolio
      • 10.9.4. Business Strategy
      • 10.9.5. Recent Development
    • 10.10. Sanofi
      • 10.10.1. Overview
      • 10.10.2. Financials
      • 10.10.3. Indication Portfolio
      • 10.10.4. Business Strategy
      • 10.10.5. Recent Development

Methodology

}
Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com